var data={"title":"Cysteine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cysteine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5966?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cysteine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cysteine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452482\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cystech [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155952\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Nutritional Supplement</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155949\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cysteine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cysteine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Nutritional supplement:</b> IV: Infants (receiving PN): Added as a fixed ratio to crystalline amino acid solution: 40 mg cysteine per 1 g of amino acids; dosage will vary with the daily amino acid dosage; (eg, 1 to 3 g/kg/day of amino acids would result in 40 to 120 mg/kg/day of cysteine); ASPEN recommends a range of 30 to 40 mg of cysteine per g of amino acids and suggests a dose as low as 20 mg per g of amino acids may be adequate and should be used in times of cysteine shortage (ASPEN Pediatric Nutrition Support Core Curriculum [Corkins, 2015]; Plogsted 2015); current practice suggests supplementation should be continued through the first year of life; practice varies widely (ASPEN Pediatric Nutrition Support Core Curriculum [Corkins 2015]; ASPEN [Mirtallo 2004]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795923\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795924\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155939\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cystech: 500 mg [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (10 mL, 50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155928\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155941\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Component of parenteral nutrition solution; must dilute in parenteral nutrition solution as a fixed ratio to crystalline amino acid solution; infuse TPN at rate as directed</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155940\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Nutritional supplement:</b> Additive to crystalline amino acid solutions to meet the intravenous (IV) amino acid nutritional requirements of infants receiving total parenteral nutrition (TPN)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155935\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing, phlebitis, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Localized warm feeling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Localized erythema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Metabolic acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Azotemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155943\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatic coma; metabolic disorders involving impaired nitrogen utilization</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155932\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperammonemia: Asymptomatic hyperammonemia has been reported. Monitor blood ammonia frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac disease: Use with caution in patients with cardiac insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Hypertonic glucose solutions should be used with caution in patients with diabetes or prediabetic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Use in this patient population may result in hyperammonemia, metabolic alkalosis, prerenal azotemia, serum amino acid imbalances, stupor and coma. In addition, peripheral IV infusion of amino acids in patients with impaired hepatic function could result in an increase in BUN (a modest rise is expected during increased protein intake).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Peripheral IV infusion of amino acids in patients with impaired renal function could result in an increase in BUN. A modest rise in BUN is to be expected during increased protein intake. Discontinue infusion if BUN levels exceed normal postprandial limits and continue to rise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary disease: Use with caution in patients with pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infants: Metabolic acidosis has occurred in infants related to the &ldquo;hydrochloride&rdquo; component of cysteine; each 1 mmol cysteine (175 mg) delivers 1 mEq chloride and 1 mEq hydrogen ion; to balance the extra hydrochloride ions and prevent acidosis addition to the TPN solution of a 1 mEq acetate electrolyte salt for each mmol (175 mg) of cysteine may be needed; each 40 mg cysteine (equal to every 1 g amino acid when used in the recommended ratio) adds 0.228 mEq chloride and hydrogen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acetate: Use acetate-containing solutions with extreme caution in patients with respiratory or metabolic alkalosis and in conditions in which there is an increased level or an impaired utilization of acetate such as severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Potassium: Use potassium-containing solutions with extreme caution, if at all, in patients with severe renal failure, hyperkalemia, and in conditions which potassium retention is present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sodium: Use sodium-containing solutions with extreme caution, if at all, in patients with severe renal impairment, heart failure, and conditions in which edema exists with sodium retention.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14079852\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Cysteine is generally considered to be a nonessential amino acid in adults because it can be synthesized from methionine (an essential amino acid). The RDA for methionine + cysteine is increased in pregnant women (IOM, 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14079853\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Cysteine is excreted in breast milk. The RDA for methionine + cysteine is increased in breast-feeding women (IOM, 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155937\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BUN, ammonia, electrolytes, acid-base balance, serum glucose, cholesterol, serum proteins; renal and hepatic function tests; WBC and blood culture; urine osmolarity and glucose; nitrogen intake; osmolarity and hemogram.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155931\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cysteine is a sulfur-containing amino acid synthesized from methionine via the transulfuration pathway. It is a precursor of the tripeptide glutathione and also of taurine. Newborn infants have a relative deficiency of the enzyme necessary to affect this conversion. Cysteine may be considered an essential amino acid in infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323086\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cystech Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $11.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (L-Cysteine HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (10 mL): $27.98</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR &sect;201.323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corkins MR, Balint J, Bobo E, et al. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)</i>, Washington, DC: The National Academies Press, 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    L-cysteine hydrochloride [prescribing information]. Princeton, NJ: Sandoz; November 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-S70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cysteine-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plogsted S, Cober P, Gura KM, et al. Parenteral nutrition L-cysteine product shortage considerations. <i>Nutr Clin Pract</i>. 2015;30(4):579-580. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cysteine-drug-information/abstract-text/26150106/pubmed\" target=\"_blank\" id=\"26150106\">26150106</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8890 Version 73.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20452482\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F155952\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F155949\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15795923\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15795924\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F155939\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F155928\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F155941\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F155940\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F155935\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F155943\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F155932\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14079852\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14079853\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F155937\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F155931\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323086\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8890|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cysteine-pediatric-drug-information\" class=\"drug drug_pediatric\">Cysteine: Pediatric drug information</a></li></ul></div></div>","javascript":null}